In this sense, the work by Fonseca et al. (80) demonstrated that the DNAhsp65 vaccine reduced the following parameters: eosinophilia, IgE production, pulmonary inflammation, airway hyperresponsiveness, Th2 cytokines, and mucus production in a manner dependent on IL-10 action and consequently impairing the establishment of airway allergy in mice (80). This evidence concerns the gene IGHE and airway hyperresponsiveness.